Veru Inc. (VERU)

NCM – Real vaqt narxi. Valyuta: USD

2.74

-0.05 (-1.79%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

2.74

0.00 (0.00%)

Bozordan keyin: Aug 12, 2026, 4:10 PM EDT

10.08.2026

Veru Inc. (VERU) Q3 2026 Earnings Call Transcript

10.08.2026

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients –

04.08.2026

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

-- When issued U.S. patent protection until at least October 2044 -- -- Allowed patent adds to already issued enobosarm specific molecule polymorph composition of matter patents, as well as number of other pending methods of use and formulation patent applications --

03.08.2026

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Monday, August 10, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 third quarter financial results and to provide a business update.

Videolar

No Data

There is no data to display

Press-relizlar

10.08.2026

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients –

04.08.2026

Veru Inc. (VERU)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Veru Inc. (VERU)

Veru Inc. (VERU) Q3 2026 Earnings Call Transcript

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

Videolar

No Data

Press-relizlar

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Veru Inc. (VERU) Q3 2026 Earnings Call Transcript

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

Videolar

No Data

Press-relizlar

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Search stocks

Veru Inc. (VERU)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Veru Inc. (VERU)

Veru Inc. (VERU) Q3 2026 Earnings Call Transcript

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

Videolar

No Data

Press-relizlar

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Veru Inc. (VERU) Q3 2026 Earnings Call Transcript

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

Videolar

No Data

Press-relizlar

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss